• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项多中心、前瞻性、观察性研究,旨在确定危重症成人中多重耐药性肺炎的预测因素:DEFINE 研究。

A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study.

机构信息

Shirley Ryan Abilitylab, Chicago, Illinois.

Dell Seton Medical Center, Austin, Texas.

出版信息

Pharmacotherapy. 2019 Mar;39(3):253-260. doi: 10.1002/phar.2171. Epub 2018 Oct 3.

DOI:10.1002/phar.2171
PMID:30101412
Abstract

OBJECTIVE

This study was conducted to describe the prevalence, epidemiology, and clinical outcomes of multidrug-resistant (MDR) organism (MDRO) pneumonia in critically ill patients.

METHODS

A multicenter, prospective, observational study of patients admitted to 60 intensive care units (ICUs), from 34 hospitals, in the United States from November to December 2016. Adults (> 18 yrs) receiving antimicrobial therapy at least 5 days for pneumonia were included. Patients were classified into two categories, with or without MDRO, and subcategorized by pneumonia type.

MEASUREMENTS AND MAIN RESULTS

Demographics, medication histories, and health care exposure were collected during ICU admission and compared using t test and chi-square tests. Multivariate logistic regression was used to determine predictive factors for MDRO pneumonia and hospital mortality. Of 652 patients, 92 patients (14.1%) developed MDR pneumonia. Predictors of MDRO pneumonia were acid suppression therapy within the previous 90 days (odds ratio [OR] 1.88 [1.14-3.09]; p=0.013), mechanical ventilation (OR 1.96 [1.14-3.35]; p<0.001), and history of MDRO infection (OR 4.74 [2.21-10.18]; p<0.001). Appropriate initial antimicrobial selection occurred in 58 patients (63%) with MDRO pneumonia compared to 464 patients (82.7%) in patients without MDRO pneumonia (p<0.001). MDRO pneumonia was not associated with hospital mortality (18.5% vs 17.6%, p=0.087).

CONCLUSIONS

In a broad cohort of critically ill patients, MDRO pneumonia is infrequent, and associated with factors describing the intensity of health care provided. Presence of MDRO pneumonia is not associated with hospital mortality. Further study is needed to clarify risk factors for multidrug-resistant pneumonia in critically ill patients.

摘要

目的

本研究旨在描述重症患者中多重耐药(MDRO)菌肺炎的流行情况、流行病学和临床结局。

方法

这是一项多中心、前瞻性、观察性研究,纳入了 2016 年 11 月至 12 月期间美国 34 家医院的 60 个重症监护病房(ICU)收治的至少接受 5 天抗菌治疗的肺炎患者。患者分为 MDRO 组和非 MDRO 组,并根据肺炎类型进行亚组分类。

测量和主要结果

在 ICU 入院时收集患者的人口统计学、用药史和医疗保健暴露情况,并使用 t 检验和卡方检验进行比较。采用多变量逻辑回归分析确定 MDRO 肺炎和医院死亡率的预测因素。在 652 名患者中,92 名(14.1%)患者发生 MDRO 肺炎。MDRO 肺炎的预测因素包括 90 天内使用胃酸抑制治疗(比值比 [OR] 1.88 [1.14-3.09];p=0.013)、机械通气(OR 1.96 [1.14-3.35];p<0.001)和 MDRO 感染史(OR 4.74 [2.21-10.18];p<0.001)。与非 MDRO 肺炎患者(82.7%)相比,92 名 MDRO 肺炎患者中有 58 名(63%)患者初始抗菌治疗选择恰当(p<0.001)。MDRO 肺炎与医院死亡率无关(18.5% vs 17.6%,p=0.087)。

结论

在广泛的重症患者队列中,MDRO 肺炎并不常见,与描述医疗保健强度的因素相关。MDRO 肺炎的存在与医院死亡率无关。需要进一步研究来阐明重症患者多重耐药性肺炎的危险因素。

相似文献

1
A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study.一项多中心、前瞻性、观察性研究,旨在确定危重症成人中多重耐药性肺炎的预测因素:DEFINE 研究。
Pharmacotherapy. 2019 Mar;39(3):253-260. doi: 10.1002/phar.2171. Epub 2018 Oct 3.
2
Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms.重症监护病房(ICU)获得性肺炎的耐药模式和结果。欧洲疾病预防控制中心(ECDC)和疾病控制与预防中心(CDC)分类的多药耐药生物体的验证。
J Infect. 2015 Mar;70(3):213-22. doi: 10.1016/j.jinf.2014.10.004. Epub 2014 Oct 27.
3
Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon outcome.医学重症监护病房中的多重耐药菌感染:与临床特征的关联及对预后的影响。
Med Intensiva (Engl Ed). 2018 May;42(4):225-234. doi: 10.1016/j.medin.2017.07.006. Epub 2017 Oct 13.
4
Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.慢性阻塞性肺疾病严重急性加重患者中的多重耐药菌:患病率、危险因素及转归
Crit Care Med. 2006 Dec;34(12):2959-66. doi: 10.1097/01.CCM.0000245666.28867.C6.
5
Stewardship Prompts to Improve Antibiotic Selection for Pneumonia: The INSPIRE Randomized Clinical Trial. stewardship 干预措施对肺炎抗生素选择的影响:INSPIRE 随机临床试验
JAMA. 2024 Jun 18;331(23):2007-2017. doi: 10.1001/jama.2024.6248.
6
Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant organism isolates in critically ill patients: a pre-post study from a single center.中国卫生部的抗菌药物管理措施减少了重症患者的多重耐药菌分离株:一项来自单一中心的前后对照研究。
BMC Infect Dis. 2016 Nov 25;16(1):704. doi: 10.1186/s12879-016-2051-8.
7
Impact of Multi-Drug-Resistant Pneumonia on Outcomes of Critically Ill Trauma Patients.多药耐药性肺炎对重症创伤患者结局的影响。
Surg Infect (Larchmt). 2020 Jun;21(5):422-427. doi: 10.1089/sur.2019.240. Epub 2020 Jan 2.
8
Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit.在重症监护病房中使用吸入抗生素降低细菌耐药性。
Am J Respir Crit Care Med. 2014 May 15;189(10):1225-33. doi: 10.1164/rccm.201312-2161OC.
9
First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs.关于中国重症监护病房多重耐药菌携带情况的首个多中心研究。
BMC Infect Dis. 2015 Aug 21;15:358. doi: 10.1186/s12879-015-1105-7.
10
Identification of Risk Factors for Multidrug-Resistant Organisms in Community-Acquired Bacterial Pneumonia at a Community Hospital.社区医院获得性细菌性肺炎中多重耐药菌的危险因素识别。
J Pharm Pract. 2023 Apr;36(2):303-308. doi: 10.1177/08971900211039700. Epub 2021 Aug 18.

引用本文的文献

1
Bacterial isolates and antibiotic resistance in critically ill sepsis patients at a tertiary hospital in Ethiopia.埃塞俄比亚一家三级医院重症脓毒症患者的细菌分离株及抗生素耐药性
BMC Infect Dis. 2025 Aug 20;25(1):1046. doi: 10.1186/s12879-025-11474-5.
2
Optimizing patient outcomes in severe pneumonia: the role of multiplex PCR in the treatment of critically ill patients.优化重症肺炎患者的治疗结局:多重聚合酶链反应在危重症患者治疗中的作用
Front Med (Lausanne). 2024 Aug 21;11:1391641. doi: 10.3389/fmed.2024.1391641. eCollection 2024.
3
Multidrug-Resistant Bacterial Colonization and Infections in Large Retrospective Cohort of Mechanically Ventilated COVID-19 Patients.
机械通气 COVID-19 患者的大型回顾性队列中的多重耐药菌定植和感染。
Emerg Infect Dis. 2023 Aug;29(8):1598-1607. doi: 10.3201/eid2908.230115.
4
Assessment of risk factors associated with multidrug-resistant organism infections among patients admitted in a tertiary hospital - a retrospective study.三级医院住院患者多重耐药菌感染相关危险因素评估——一项回顾性研究
Saudi Pharm J. 2023 Jun;31(6):1084-1093. doi: 10.1016/j.jsps.2023.03.019. Epub 2023 Mar 31.
5
The Prevalence of Carbapenemase-Producing Microorganisms and Use of Novel Cephalosporins for the Treatment of Severe Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria in a Pediatric Cardiac Intensive Care Unit.儿科心脏重症监护病房中产碳青霉烯酶微生物的流行情况以及新型头孢菌素用于治疗耐碳青霉烯革兰氏阴性菌引起的严重感染的情况
Antibiotics (Basel). 2023 Apr 22;12(5):796. doi: 10.3390/antibiotics12050796.
6
Optimization of Therapy and the Risk of Probiotic Use during Antibiotherapy in Septic Critically Ill Patients: A Narrative Review.优化治疗策略与益生菌在脓毒症危重症患者抗生素治疗期间应用的风险:一项叙述性综述。
Medicina (Kaunas). 2023 Feb 28;59(3):478. doi: 10.3390/medicina59030478.
7
Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany.德国耐多药革兰氏阴性菌所致肺炎的重症监护病房(ICU)真实患者的挽救性抗生素成本及报销分析
Healthcare (Basel). 2022 Dec 15;10(12):2546. doi: 10.3390/healthcare10122546.
8
Clinical Characteristics and Outcome of MDR/XDR Bacterial Infections in a Neuromuscular Semi-Intensive/Sub-Intensive Care Unit.神经肌肉半强化/亚强化护理单元中多重耐药/广泛耐药细菌感染的临床特征与转归
Antibiotics (Basel). 2022 Oct 13;11(10):1411. doi: 10.3390/antibiotics11101411.
9
Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.头孢地尔在连续肾脏替代治疗期间的药代动力学、药效学和剂量优化。
Clin Pharmacokinet. 2022 Apr;61(4):539-552. doi: 10.1007/s40262-021-01086-y. Epub 2021 Nov 18.
10
Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center Experience.心脏移植后多重耐药感染的危险因素及结局:一项当代单中心经验
Microorganisms. 2021 Jun 3;9(6):1210. doi: 10.3390/microorganisms9061210.